Open for inclusion

A Phase II, Open-label, Study in Subjects with BRAF V600EMutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combiantion Therapy of Dabrafenib and Trametinib

Cancer type: Solide tumores

Phase: II

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden

Status: Open for inclusion

Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT02034110?term=braf&recr=Open&phase=1&rank=10